James Hussey Email

CEO . Seneca Therapeutics

Current Roles

Employees:
12
Revenue:
$1.9M
About
Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.
Seneca Therapeutics Address

Philadelphia, PA
United States
Seneca Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.